News & Updates
Showing Multidisciplinary articles
Showing

Belzutifan a ray of hope for VHL-associated renal cancer?
In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.

Biologic-naïve IBD patients on anti-TNFα warrant treatment intensification
Treatment intensification is needed in around one-third of biologic-naïve patients with inflammatory bowel disease (IBD) who had received initial antitumour necrosis factor α (anti-TNFα) medication, a recent study has found.

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

Chronic constipation patients unhappy with conventional treatments: survey
Conventional treatment options for chronic constipation (CC) are not effective enough to improve symptoms or satisfaction among patients, results of an internet survey in Japan have shown.




